Jullet Han, MD
Urology · Los Angeles, CANPI 1407218050
Payments from drug & device makers
What this record shows
This record is dominated by education: $70,750 of the $104,943 with a category attached, or 67.4%. Intuitive Surgical accounts for 97.5% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $39,997, more than ten times the $254 reported in 2019. Among urology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 179 payments — averaging $586.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$102K
- Boston Scientific$765
- Urogen Pharma, Inc.$265
- Procept Biorobotics Corporation$254
- Ferring Pharmaceuticals Inc.$250
- Photocure Inc$241
- plus $869 from 12 others
What the payments were for
- Speaking & faculty fees$12,00011%
- Travel & lodging$13,06212%
- Food & beverage$9,0999%
- Education$70,75067%
- Gifts$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 142 | $102,299 |
| Boston Scientific | 14 | $765 |
| Urogen Pharma, Inc. | 2 | $265 |
| Procept Biorobotics Corporation | 2 | $254 |
| Ferring Pharmaceuticals Inc. | 3 | $250 |
| Photocure Inc | 3 | $241 |
| Histosonics, Inc. | 1 | $145 |
| Progenics Pharmaceuticals, Inc. | 1 | $125 |
| Johnson & Johnson | 1 | $123 |
| Teleflex LLC | 1 | $118 |
| EMD Serono, Inc. | 2 | $83 |
| Astellas Pharma US Inc | 1 | $78 |
| Stryker | 1 | $71 |
| AbbVie | 1 | $35 |
| Epizyme, Inc. | 1 | $25 |
| Medtronic | 1 | $24 |
| Sanofi | 1 | $21 |
| SK Life Science, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$82,410
- DA VINCI SP$15,145
- DAVINCI XI$3,000
- ADSTILADRIN$232
- AquaBeam Robotic System$198
- LithoVue$184
- Cysview$149
- JELMYTO$146
- PYLARIFY$125
- AMS$125
- Erleada$123
- ZUSDURI$119
- UroLift System$118
How this compares
$104,943 in reported general payments places this provider in the 95th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 128 | $78,272 |
| OrgovyxRelugolix | 20 | $52,852 |
| Estradiol | 63 | $4,875 |
| Tolterodine Tartrate ErTolterodine Tartrate | 41 | $4,068 |
| Tamsulosin Hcl | 105 | $1,636 |
| Finasteride | 124 | $1,494 |
| Cefpodoxime Proxetil | 19 | $785 |
| Cefdinir | 12 | $174 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 32 | $83 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $78 | $78,272128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,324 urology providers in California.
Other urology in Los Angeles
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
- Stuart HoldenLos Angeles$1.1M
- William AronsonLos Angeles$540K
- Amir LebastchiLos Angeles$478K
- Nazy ZomorodianLos Angeles$309K
- Jeffrey Loh-DoyleLos Angeles$308K
- Siamak DaneshmandLos Angeles$306K
- Karim ChamieLos Angeles$291K
- Brian ShuchLos Angeles$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.